Table 2 Univariable analysis of patient characteristics and FRα H-score with invasive disease-free survival and overall survival.
IDFS | OS | |||
|---|---|---|---|---|
HR (95% CI) | P-value | HR (95% CI) | P-value | |
Age | ||||
<45.0 | 1.0 (ref) | 1.0 (ref) | ||
45.0–54.3 | 0.85 (0.54–1.32) | 0.46 | 0.83 (0.48–1.41) | 0.483 |
54.4–65.7 | 0.92 (0.58–1.46) | 0.72 | 1.52 (0.93–2.49) | 0.091 |
65.8–88.4 | 1.44 (0.92–2.26) | 0.11 | 3.01 (1.92–4.70) | <0.001 |
Menopausal status | ||||
Pre/peri | 1.0 (ref) | 1.0 (ref) | ||
Post | 1.31 (0.94–1.81) | 0.11 | 2.37 (1.66–3.38) | <0.001 |
Tumor size | ||||
T1 (0.1–2.0 cm) | 1.0 (ref) | 1.0 (ref) | ||
T2 (2.1–5.0 cm) | 0.94 (0.68–1.32) | 0.73 | 1.11 (0.80–1.55) | 0.53 |
T3/4 (5.1+ cm) | 1.7 (0.94–3.06) | 0.08 | 1.95 (1.10–3.46) | 0.02 |
Nodal status | ||||
N0 | 1.0 (ref) | 1.0 (ref) | ||
N1 | 1.36 (0.92–2.02) | 0.13 | 1.59 (1.06–2.40) | 0.03 |
N2 | 1.84 (1.1–3.06) | 0.02 | 2.64 (1.63–4.28) | <0.0001 |
N3 | 3.44 (2–6.27) | <0.0001 | 3.59 (2.12–6.09) | <0.0001 |
NX | 3.58 (0.88–14.60) | 0.08 | 6.96 (2.53–19.20) | 0.0002 |
Histology | ||||
Invasive carcinoma NST | 1.0 (ref) | 1.0 (ref) | ||
Metaplastic carcinoma NST | 0.96 (0.53–1.74) | 0.88 | 0.63 (0.30–1.28) | 0.20 |
Ca. with apocrine differentiation | 1.15 (0.64–2.05) | 0.64 | 1.11 (0.64–1.94) | 0.71 |
Ca. with medullary features | 0.60 (0.38–0.96) | 0.03 | 0.60 (0.38–1.28) | 0.03 |
Nottingham grade | ||||
1 | 1.0 (ref) | 1.0 (ref) | ||
2 | 0.49 (0.11–2.14) | 0.34 | 0.568 (0.13–2.49) | 0.45 |
3 | 0.32 (0.08–1.32) | 0.12 | 0.398 (0.10–1.61) | 0.2 |
Ki-67 grouping | ||||
≤15% | 1.0 (ref) | 1.0 (ref) | ||
15.1–30% | 0.76 (0.44–1.33) | 0.34 | 0.56 (0.32–1.00) | 0.05 |
>30% | 1.06 (0.71–1.60) | 0.77 | 0.84 (0.57–1.24) | 0.38 |
Stromal TILs (per 10% increment) | 0.88 (0.81–0.95) | 0.002 | 0.88 (0.81–0.95) | 0.001 |
FRα H-score | ||||
0 | 1.0 (ref) | 1.0 (ref) | ||
0.25–52.5 | 0.55 (0.35–0.88) | 0.01 | 0.59 (0.37–0.93) | 0.02 |
52.5–140 | 0.64 (0.41–1.00) | 0.05 | 0.79 (0.51–1.21) | 0.28 |
140–300 | 0.84 (0.56–1.26) | 0.4 | 0.901 (0.60–1.38) | 0.65 |
FRα H-score | ||||
≤49.375 (median) | 1.0 (ref) | 1.0 (ref) | ||
>49.375 (median) | 0.94 (0.69–1.30) | 0.73 | 1.07 (0.78–1.47) | 0.67 |
FRα H-score | ||||
0 | 1.0 (ref) | 1.0 (ref) | ||
>0 | 0.68 (0.49–0.94) | 0.02 | 0.75 (0.54–1.06) | 0.10 |
Surgery type | ||||
Lumpectomy | 1.0 (ref) | 1.0 (ref) | ||
Mastectomy | 1.06 (0.77–1.46) | 0.72 | 1.35 (0.97–1.88) | 0.07 |
Adjuvant chemotherapy | ||||
No | 1.0 (ref) | 1.0 (ref) | ||
Yes | 0.79 (0.56–1.10) | 0.16 | 0.7 (0.49–0.99) | 0.04 |
Unknown | 1.18 (0.51–2.74) | 0.71 | 1.57 (0.96–2.59) | 0.07 |
Adjuvant radiotherapy | ||||
No | 1.0 (ref) | 1.0 (ref) | ||
Yes | 0.94 (0.67–1.30) | 0.7 | 0.73 (0.52–1.04) | 0.08 |
Unknown | 1.06 (0.42–2.64) | 0.91 | 1.5 (0.92–2.45) | 0.1 |
